Samsung Bioepis signs $1.29 billion contract with US pharmaceutical company

On September 9th, Sanxing Biotech announced that it has signed a contract worth $1.29464 billion with a pharmaceutical company in the United States for contract manufacturing. This contract is the second largest since the company was founded, and it will be valid until December 31, 2029. According to the confidentiality agreement, the client and product names will not be disclosed.